Business Context and Reporting Period
Filing identity: The supplied filing is a Form 10-Q for Neuralstem, Inc., not Palisade Bio, Inc. It covers the quarter ended March 31, 2018 and was filed May 15, 2018. Neuralstem is a clinical-stage biopharmaceutical company developing neural stem-cell therapies and small-molecule compounds for central nervous system diseases.
The company reported six full-time employees as of April 30, 2018. Its principal programs included NSI-189 for major depressive disorder and NSI-566 stem-cell therapy programs for ALS, stroke, and chronic spinal cord injury.
Key Financial Metrics
| Metric | Three Months Ended March 31, 2018 | Three Months Ended March 31, 2017 |
|---|---|---|
| Revenue | $2,500 | $2,500 |
| Research and development expense | $1.17 million | $2.90 million |
| General and administrative expense | $1.18 million | $1.33 million |
| Total operating expenses | $2.35 million | $4.23 million |
| Operating loss | $2.35 million | $4.23 million |
| Net loss | $2.15 million | $7.57 million |
| Basic and diluted loss per share | $0.14 | $0.68 |
| Net cash used in operating activities | $1.85 million | $4.44 million |
Revenue consisted of ongoing licensing fees; the company generated no revenue from commercial product sales. Operating and net loss margins are not meaningful because revenue was only $2,500.
| Balance Sheet Metric | March 31, 2018 | December 31, 2017 |
|---|---|---|
| Cash and cash equivalents | $9.72 million | $6.67 million |
| Short-term investments | None | $5.00 million |
| Total current assets | $10.21 million | $12.45 million |
| Total current liabilities | $1.28 million | $1.51 million |
| Warrant liabilities | $3.66 million | $3.85 million |
| Total liabilities | $4.94 million | $5.37 million |
| Stockholders’ equity | $6.61 million | $8.52 million |
Investing activities provided $5.00 million from the maturity of short-term investments. Financing activities used $104,244, consisting of payments on short-term debt. The filing does not present a separately identifiable total debt balance beyond these short-term debt payments and warrant liabilities.
Material Changes Versus the Prior Comparable Period
- Research and development expense decreased 60%, or $1.73 million, primarily because the NSI-189 Phase 2 trial was completed, personnel and facility costs declined following restructuring, and share-based compensation decreased.
- General and administrative expense decreased 11%, or $150,367, largely due to lower payroll, consulting, and professional-service costs.
- Net loss improved by $5.42 million, primarily because the prior-year period included a $2.74 million non-cash loss on warrant fair value, $476,084 of warrant inducement expense, and $138,732 of interest expense.
- Operating cash use declined by $2.59 million, or 58%, to $1.85 million.
- Cash and cash equivalents increased by $3.05 million during the quarter, principally because the $5.00 million short-term investment matured.
- The liability-classified warrant balance declined from $3.85 million to $3.66 million, producing a $190,219 non-cash gain.
- Weighted-average common shares outstanding increased to 15.1 million from 11.1 million, while year-end issued and outstanding common shares remained 15,160,014.
Guidance, Outlook, Risks, and Unusual Items
Management expected existing cash and cash equivalents to fund anticipated operations into the first quarter of 2019, based on current plans and an expected decrease in the average monthly cash burn rate. The company stated that it would require additional capital to continue developing its preclinical and clinical programs and expected to pursue equity or debt offerings, grants, collaborative arrangements, or licensing transactions.
The financial statements disclosed substantial doubt about the company’s ability to continue as a going concern within one year after issuance. No future funding commitments existed. Failure to obtain financing could require the company to delay, reduce, or eliminate research programs and clinical trials, license assets on unfavorable terms, cease operations, or seek bankruptcy protection.
- NSI-189’s Phase 2 major depressive disorder trial failed to meet its primary efficacy endpoint, although certain secondary results were directionally positive.
- NSI-566 clinical programs remained dependent on successful safety and efficacy results, regulatory approvals, third-party manufacturers, clinical research organizations, and specialized surgical procedures.
- The company had no approved commercial products and did not expect profitability in the next several years.
- The company had an effective shelf registration statement permitting up to $100 million of securities offerings; approximately $10.5 million had been sold or reserved against it through March 31, 2018.
- Approximately 2.98 million liability-classified warrants remained outstanding at March 31, 2018, and approximately 6.3 million common shares were reserved for equity awards.
- The company received approximately $84,000 of SBIR grant reimbursements recorded as a reduction of research and development expense during the quarter.
- A related-party receivable had a principal amount of approximately $458,000, payable in annual installments through July 2022, arising from a reimbursement agreement with a former executive.
- No material litigation was pending, according to the filing, and management stated that disclosure controls were effective as of March 31, 2018.
Investor Verification Items
- Verify the issuer name and ticker because the provided metadata identifies Palisade Bio, Inc., while the filing itself identifies Neuralstem, Inc.
- Assess the going-concern disclosure, projected cash runway into the first quarter of 2019, and the company’s ability to secure additional financing.
- Reconcile cash availability with the $1.85 million quarterly operating cash burn and expected future clinical-development spending.
- Review the terms, exercise prices, settlement provisions, and potential dilution from outstanding warrants, preferred stock, options, and other equity-linked instruments.
- Evaluate the implications of the failed NSI-189 primary endpoint and the evidentiary strength of the company’s remaining clinical programs.
- Confirm regulatory, manufacturing, clinical-trial, intellectual-property, and third-party execution risks before assigning value to the pipeline.